IMARC Group has recently released a new research study titled “Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios.
How big is the hospital acquired disease testing market?
The global hospital acquired disease testing market size reached US$ 10.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 27.7 Billion by 2028, exhibiting a growth rate (CAGR) of 17.57% during 2023-2028.
Hospital Acquired Disease Testing: Definition and Application:
Hospital-Acquired Disease Testing, also known as nosocomial infection testing or healthcare-associated infection (HAI) testing, refers to the process of diagnosing infections that patients acquire during their stay in a healthcare facility, which were not present or incubating at the time of admission. The testing primarily focuses on infections such as urinary tract infections, surgical site infections, bloodstream infections, and pneumonia, among others. These infections can be caused by a variety of pathogens, including bacteria, fungi, and viruses. The tests involved range from traditional culture tests to advanced molecular diagnostics.
Hospital-acquired disease testing usually involves a comprehensive array of diagnostic tools and techniques, including microbial culture, PCR, immunoassays, and newer technologies such as next-generation sequencing and multiplexed diagnostic assays. The key feature of these tests is their ability to quickly and accurately identify the causative agent, allowing for prompt and appropriate treatment. This type of testing is a crucial aspect of the healthcare industry, specifically in hospitals, clinics, and other medical facilities.
Request to Get the Sample Report: https://www.imarcgroup.com/hospital-acquired-disease-testing-market/requestsample
Hospital Acquired Disease Testing Market Growth Drivers and Trends:
The rising incidence of hospital-acquired infections globally is driving the demand for hospital-acquired disease testing. Moreover, advancements in technology are enabling quicker, more accurate tests, stimulating market growth. The increasing awareness about hospital-acquired infections among healthcare professionals and patients is contributing to market expansion.
The growth of antibiotic-resistant bacteria is pushing the need for rapid diagnostic testing. Growing government initiatives to control and prevent hospital-acquired infections are propelling the market growth. The increasing number of surgeries being performed worldwide is escalating the demand for such tests. The rising healthcare expenditure and investments in healthcare infrastructure are fueling market growth. The growing trend of outsourcing laboratory services is contributing to the market expansion. The ongoing development of novel diagnostic techniques is stimulating market growth. The increasing demand for advanced healthcare facilities in developing countries is driving the market. The rising awareness and concerns about patient safety are escalating the demand for these tests.
A growing number of immunocompromised patients, who are more susceptible to such infections, are pushing the market growth. The implementation of strict guidelines and recommendations for infection control is contributing to market expansion. The surge in healthcare-associated pneumonia cases is escalating the demand for hospital-acquired disease testing. High patient turnover rates in hospitals are pushing the demand for rapid and effective testing methods. The expanding elderly population, who are more prone to these infections, is driving market growth.
Increasing incidences of device-related infections are stimulating the demand for these tests. The rise of molecular diagnostics, providing high accuracy and speed, is pushing the market growth. The growing prevalence of chronic diseases requiring prolonged hospital stays is escalating the market demand. The ongoing COVID-19 pandemic has highlighted the need for stringent infection control, contributing significantly to the market growth.
Hospital Acquired Disease Testing Market 2023-2028 Competitive Analysis and Segmentation:
Competitive Landscape With Key Players:
The competitive landscape of the hospital acquired disease testing market has been studied in the report with the detailed profiles of the key players operating in the market.
Major Players Covered:
- Abbott Laboratories
- Alere, Inc.
- Becton, Dickinson and Company
- bioMérieux SA
- Hoffmann-La Roche Ltd.
- Hologic, Inc.
- QIAGEN
- Siemens Healthcare
- Diatherix Laboratories, Inc.
- Meridian Bioscience, Inc.
- Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
- Cepheid, Inc.
Report Segmentation:
The report has segmented the hospital acquired disease testing market on the basis of indication and region.
Based on Indication:
- UTI (Urinary Tract Infection)
- SSI (Surgical Site Infection)
- Pneumonia
- Bloodstream Infections
- MRSA (Methicillin-Resistant Staphylococcus Aureus)
- Others
Geographical Analysis:
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East and Africa
Speak to Analyst: https://www.imarcgroup.com/request?type=report&id=1128&flag=C
Key Highlights of the Report:
- Market Performance (2017-2022)
- Market Outlook (2023-2028)
- Industry Trends
- Market Drivers and Success Factors
- The Impact of COVID-19 on the Global Market
- Value Chain Analysis
- Structure of the Global Market
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Media Contact:
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: sales@imarcgroup.com
Phone: +1-631-791-1145
Address: 134 N 4th St
City: Brooklyn
State: NY
Country: United States
Website: https://www.imarcgroup.com
